Evolus, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolus, Inc. on December 13, 2022, regarding events occurring on December 12, 2022. The Company is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Global Market under the symbol EOLS.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a material definitive agreement.
Material Changes and Agreements
On December 12, 2022, Evolus, Inc. entered into a Fourth Amendment to its License and Supply Agreement with Daewoong Pharmaceuticals Co., Ltd. Key provisions include:
- Pricing Modification: The transfer price for Nuceiva® in certain European countries has changed from a fixed price to a price based on net sales in those countries.
- Territorial Rights: The Company has relinquished its rights to sell neurotoxin manufactured by Daewoong in Russia.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the implications of the amended agreement. The full text of the Fourth Amendment is filed as Exhibit 10.1, with certain confidential portions redacted.
Key Facts for Investor Verification
- Review Exhibit 10.1 to understand the specific European countries affected by the pricing change and the calculation methodology for the new net sales-based price.
- Assess the financial impact of relinquishing rights to sell neurotoxin in Russia on future revenue projections.
- Verify if the pricing model change alters the Company's gross margin profile for the European region.